Postby roadrunner » Fri Aug 13, 2021 12:43 pm
I don’t believe it would be appropriate or practical to apply a bright line to this. “Immunocompromised” is a fine line and a moving target. Most solid tumor patients respond better than many solid transplant patients. However, solid tumor patients respond poorly to one shot (far below healthy controls) but better to a second shot. That said, even then their numbers are often lower than those of controls—especially but not exclusively if on active therapy—and with time from previous immunization (immunity wanes) and new variant vaccine escape as relatively ill-defined variables, it’s really individual, and really hard to know in an individual case. For example, pelvic radiation treatment (usually for RC) can have long-term (years of) immunosuppressive effects (and even then the type and amount of radiation matters). Blood counts may give you an idea of where you stand in general, but aren’t dispositive. Even antibody titer doesn’t decide the issue, because T-cell response is also crucial. Thus, this should—and I believe ultimately will—be a personal evaluation by patients and their doctors. Plus, can CVS and Walgreen’s really make these calls?
Last edited by
roadrunner on Fri Aug 13, 2021 1:45 pm, edited 1 time in total.
7/19: RC: Staged IIIA, T2N1M0
approx 4.25 cm, low/mid rectum, mod. well diff.; lung micronodule
8/19-10/19 4 rds.FOLFOX neoadjuvant, 3 w/Oxiplatin (reduced 70-75%)
neoadjuvant chemorad 11/19
4 rounds FOLFOX July-August 2020
ncCR 10/20; biopsies neg
TAE 11/20, tumor cells removed
Chest CT 3/30/21 growth in 2 nodules (3 and 5mm)
VATS 12/8/21 sub-pleural met 7mm.
SBRT nodule 1/22
6/20/22 TAE rectal polyp benign)
NED from 3/22 - 3/23
4 cycles FOLFIRI
LUL VATS lobectomy for radio resistant met 7/7/23